Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians and consumers alike understand the advanced changes that can be made within a medical setting - and physicians are realizing the supportive role that Estheticians can bring to their practices. Working in a medical setting as an Esthetician can be both rewarding and beneficial for both yourself and your clients alike.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

MARCH 3, 2025

“The launch of BioRewind marks a significant milestone for skinbetter science and medical grade skincare,” says Jonah Shacknai, CEO of skin better science. ” A double-blinded, randomized, placebo-controlled trial evaluated the safety and efficacy of BioRewind in 104 patients over 12-weeks. In a news release.

Medical Grade Skincare 74

Medical Grade Skincare Social Media Branding Skin Health 74

The Dermatology Digest

JULY 24, 2024

We will prioritize quality, broaden choices for medical professionals, and provide superior experiences and accessibility to the consumers.” The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology appeared first on The Dermatology Digest.

Dermatology 78

Dermatology Sales Marketing Safety 78

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

FEBRUARY 18, 2025

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. The post U.S

Networking 64

Networking Innovations Safety Management 64

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. ” Comprehensive results from both ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions. achieving PASI-90.

Safety 36

Safety Medical Innovations Dermatology 36

West Lake Dermatology

JANUARY 10, 2025

This comprehensive guide will help you recognize red flags, ask the right questions, and prioritize your safety. Always verify a provider’s licensing through official state medical boards. Check for FDA Approval The FDA regulates cosmetic injectables like Botox, Juvederm, and Restylane to ensure safety and efficacy.

Legal 36

Legal Injections Safety Ethics 36

The Dermatology Digest

NOVEMBER 30, 2024

Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus. Stay tuned.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MARCH 10, 2025

improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. ” The post Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO appeared first on The Dermatology Digest. In addition, 29.4% in the placebo group.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

MARCH 10, 2025

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication.

Dermatitis 36

Dermatitis Safety Office Eczema 36

US Dermatologt Partners

JANUARY 13, 2025

Dermatology Partners Fairfax , Whether patients are dealing with persistent blackheads, painful cystic acne, or stubborn whiteheads, the temptation to pop or pick at acne is hard to resist. They also use topical and/or injected numbing medications to make the procedure more comfortable. According to Dr. Kavya Desai of U.S.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The company is currently preparing for Phase 2/3 trials with anticipated initiation in 1Q 2025.

Treatments 36

Treatments Office Therapy Clinic 36

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Journal of the American Academy of Dermatology. Dermatologic Therapy. Journal of Cosmetic Dermatology. Dermatology Clinics. Dermatology Clinics.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

MARCH 8, 2025

The research was presented as a late-breaker at the 2025American Academy of Dermatology(AAD) Annual Meeting inOrlando, FL. The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% The overall safety profile of ruxolitinib cream 1.5%

Safety 36

Safety Clinic Therapy Dermatology 36

The Dermatology Digest

OCTOBER 16, 2024

Due to Dr. Gross’s work, Georgia is taking proactive steps to accurately define “cosmetic laser services” and ensuring these medical procedures are considered the practice of medicine to best protect patients. We appreciate their hard work and dedication to promoting and protecting patient safety.

Safety 36

Safety Surgery Office Dermatology 36

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up. 75mg: 40.6% 75mg: 42.3%

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

MARCH 18, 2025

It is designed to assess the safety and efficacy of aminolevulinic acid hydrochloridePDT following the application of 1-3 tubes of product over a surface area (continuous or in patches) of approximately 80, 160 or 240cm 2.

Treatments 36

Treatments Dermatology Safety Therapy 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Innovations Safety 36

The Dermatology Digest

MARCH 9, 2025

Results from the pivotal ADEPT Phase 2/3 trial were shared in a late-breaking oral presentation at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

The Dermatology Digest

NOVEMBER 6, 2024

” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.

Hospital 36

Hospital Therapy Management Networking 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Dr. Krystal Briglia, L+A Medical + Wellness Editor Dr. Krystal Briglia of Triada Integrative Medicine + Wellness is a board-certified nurse practitioner specializing in aesthetic dermatology, integrative medicine, and wellness. Journal of Dermatological Science. Journal of the American Academy of Dermatology. Farris, P.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Texas Dermatology

JANUARY 26, 2025

At Texas Dermatology, we offer Botox and Dysport as two of the most popular non-surgical solutions for smoothing fine lines and wrinkles, helping you achieve a refreshed, youthful appearance. Both treatments are FDA-approved and trusted for their safety, effectiveness, and natural-looking results. What Is Botox?

Wrinkles 36

Wrinkles Injections Med Spa Safety 36

The Dermatology Digest

MARCH 14, 2025

. “At the NFL, we’re always looking for new ways to provide the highest level of care to our players, including through collaboration with experts across the medical field. ” The post Touchdown: Novartis Named First-ever Corporate Pharmaceutical Partner of the NFL appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Partnerships Medical Office 36

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Dermatology 74

Dermatology Safety Clinic Therapy 74

The Dermatology Digest

AUGUST 20, 2024

There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population. The adverse events were consistent with the known safety profile of Otezla in adult patients. sPGA response for Otezla versus 10.8% for placebo (95% CI: 12.2%, 32.4%. For more information, visit Otezla.com.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

DECEMBER 13, 2024

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

MARCH 7, 2025

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.

Skin Health 46

Skin Health Medical Safety Technology 46

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 2, 2024

New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. What’s New in ‘Natural’ Sunscreens?

Ingredients 74

Ingredients Safety Innovations Dermatology 74

Texas Dermatology

OCTOBER 20, 2023

However, it’s crucial to prioritize safety when applying makeup to your skin. In this blog, we’ll discuss Halloween makeup safety tips, what to do if you encounter a bad skin reaction, and why scheduling a dermatology appointment at Texas Dermatology is essential for addressing skin issues.

Makeup 36

Makeup Safety Skin Issues Irritation 36

The Dermatology Digest

SEPTEMBER 23, 2024

These trials evaluated the safety and efficacy of delgocitinib compared to cream vehicle. This news is testament to our dedication to making a fundamental difference for those who need us most in medical dermatology. Both trials met their primary and all secondary endpoints. with the same determination and dedication.”

Eczema 66

Eczema Safety Dermatology Clinic 66

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

JANUARY 5, 2024

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea. The post Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29 appeared first on The Dermatology Digest.

Rosacea 36

Rosacea Medical Office Clinic 36

West Lake Dermatology

SEPTEMBER 24, 2024

In the ever-evolving world of weight loss treatments, GLP-1 agonists like semaglutide (the active ingredient in popular medications like Ozempic or Wegovy) and tirzepatide (the active ingredient in Mounjaro) have rapidly gained popularity. of their body weight over 68 weeks, compared to just 2.4% in the placebo group.

Medical 36

Medical Diet Safety Sustainability 36